Deprescribing in Patients with Intellectual Disability.

Q3 Medicine
Innovations in clinical neuroscience Pub Date : 2025-06-01 eCollection Date: 2025-04-01
Larrilyn Grant, Kari Harper, Julie P Gentile
{"title":"Deprescribing in Patients with Intellectual Disability.","authors":"Larrilyn Grant, Kari Harper, Julie P Gentile","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Department editor: </strong>Julie P. Gentile, MD, is Professor and Chair of the Department of Psychiatry at Wright State University in Dayton, Ohio.</p><p><strong>Editor’s note: </strong>The patient scenarios presented in this article are composite cases written to illustrate certain diagnostic characteristics and to instruct on treatment techniques. The composite cases are not real patients in treatment. Any resemblance to real patients is purely coincidental.</p><p><strong>Abstract: </strong>The prevalence of mental illness in individuals with intellectual disability (ID) is higher compared to the general population. Persons with ID typically have insufficient coping skills and fewer systems of natural support; they are often more vulnerable to stress. There is evidence that level of intelligence is not a sole indicator for appropriateness for psychotherapy, and that the full range of mental health services help improve quality of life for patients with ID. Polypharmacy is more common in patients with co-occurring ID and mental illness. It is common for patients with ID to be prescribed multiple medications for both physical and mental health conditions. In addition, when patients are discharged from state-operated institutions to the community, it is common for them to continue taking the same number of medications. This article will review the use of adapted psychotherapy in patients with ID, as well as deprescribing protocols to address polypharmacy.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 4-6","pages":"29-37"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333497/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovations in clinical neuroscience","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Department editor: Julie P. Gentile, MD, is Professor and Chair of the Department of Psychiatry at Wright State University in Dayton, Ohio.

Editor’s note: The patient scenarios presented in this article are composite cases written to illustrate certain diagnostic characteristics and to instruct on treatment techniques. The composite cases are not real patients in treatment. Any resemblance to real patients is purely coincidental.

Abstract: The prevalence of mental illness in individuals with intellectual disability (ID) is higher compared to the general population. Persons with ID typically have insufficient coping skills and fewer systems of natural support; they are often more vulnerable to stress. There is evidence that level of intelligence is not a sole indicator for appropriateness for psychotherapy, and that the full range of mental health services help improve quality of life for patients with ID. Polypharmacy is more common in patients with co-occurring ID and mental illness. It is common for patients with ID to be prescribed multiple medications for both physical and mental health conditions. In addition, when patients are discharged from state-operated institutions to the community, it is common for them to continue taking the same number of medications. This article will review the use of adapted psychotherapy in patients with ID, as well as deprescribing protocols to address polypharmacy.

智力残疾患者的处方处方。
部门编辑:Julie P. Gentile,医学博士,俄亥俄州代顿市莱特州立大学精神病学教授和系主任。编者注:本文中提出的患者情况是复合病例,旨在说明某些诊断特征并指导治疗技术。复合病例在治疗中并不是真正的病人。与真实病人的相似纯属巧合。摘要/ Abstract摘要:智力残疾(ID)个体的精神疾病患病率高于普通人群。患有ID的人通常缺乏应对技能和较少的自然支持系统;他们往往更容易受到压力的影响。有证据表明,智力水平并不是心理治疗是否合适的唯一指标,而且全方位的心理健康服务有助于改善ID患者的生活质量。多重用药在同时患有ID和精神疾病的患者中更为常见。对于患有ID的患者来说,为身体和精神健康状况开出多种药物是很常见的。此外,当患者从国营机构出院到社区时,他们继续服用相同数量的药物是很常见的。本文将回顾适应心理治疗在ID患者中的应用,以及解决多重用药的处方方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Innovations in clinical neuroscience
Innovations in clinical neuroscience Medicine-Psychiatry and Mental Health
CiteScore
2.10
自引率
0.00%
发文量
87
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信